Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Afamelanotide (brand name Scenesse) is a synthetic 13-amino-acid analogue of α-melanocyte-stimulating hormone (α-MSH) and a melanocortin-1 receptoragonist. Unlike most peptides covered here, it is a regularly approved medicine: EMA approval in 2014/2015, FDA approval in 2019, in each case as a subcutaneous implant for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It promotes eumelanin formation in the skin.
Researched for
Prevention of phototoxicity in erythropoietic protoporphyria (approved indication)Photoprotection via eumelanin formationInvestigated, non-approved dermatology uses (e.g. vitiligo)
Official status
US: Prescription
Approved by the FDA in 2019 as Scenesse (subcutaneous implant) to increase pain-free light exposure in adults with erythropoietic protoporphyria — prescription only.
Afamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone. It differs from native α-MSH by two substitutions — norleucine at position 4 and D-phenylalanine at position 7 — which make it metabolically more stable and more potent. As an agonist at the melanocortin-1 receptor (MC1R) on melanocytes, it activates adenylate cyclase, raises cAMP and increases tyrosinase activity via the transcription factor MITF. This shifts pigment synthesis toward eumelanin, which absorbs UV and visible light and has antioxidant properties — the presumed mechanism of photoprotection in EPP.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · 2 tiers
Human RCT
1
Human trial
3
03
What the studies show
Human RCT
Mensch
Langendonk JG. et al. 2015
Prolonged pain-free sunlight exposure in patients with erythropoietic protoporphyria compared with placebo
What does NOT follow: Demonstrated in two randomized, placebo-controlled trials; effect size differed between the US and EU cohorts. Applies to the rare disease EPP and is not transferable to healthy individuals. Not a usage recommendation.
Human trial
Mensch
Minder EI., Barman-Aksözen J. 2015
Increase in skin eumelanin pigmentation as a pharmacodynamic effect
What does NOT follow: Pigmentation is the expected pharmacodynamic marker, not the clinical endpoint itself. Described in review articles.
Human trial
Mensch (prospektive Kohorte)
Wensink D., Wagenmakers MAEM., Barman-Aksözen J. et al. 2020
Improvement in reported quality of life and more time spent outdoors under real-world conditions
What does NOT follow: From a single-center prospective observational cohort without a placebo arm; self-report and lack of blinding limit conclusiveness relative to the RCTs.
Human trial
Mensch (Langzeit-Kohorte)
Biolcati G. et al. 2015
Predominantly mild, self-limiting adverse effects such as nausea, fatigue and headache in long-term observation
What does NOT follow: Long-term observational data over up to eight years and more than a thousand implants; observational design without a control group. Safety assessment rests with the regulatory authorities.
04
Where studies disagree
Open question
How should the melanoma-surveillance risk of a melanocortin agonist be weighed against the EPP benefit?
POSITION A
Afamelanotide is approved for erythropoietic protoporphyria (EPP) and markedly extends pain-free sunlight tolerance — a clear benefit for patients.
POSITION B
As a melanocortin agonist it promotes pigmentation and can alter moles; regular dermatological monitoring is mandated.
CURRENT STATE · In the approved EPP indication the benefit prevails under skin monitoring; cosmetic/off-label use shifts the benefit-risk balance unfavourably.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 12 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
The approved form is a subcutaneously placed, biodegradable implant that releases the active substance over several days. Factual description only, not an application guide.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Nausea
Described as predominantly mild and self-limiting in the post-authorization cohort.
in Studien und Kohorten berichtet
Human trial
Headache
Common, mostly mild adverse effect in the clinical trials.
in Studien berichtet
Human trial
Fatigue
Described as self-limiting in the observational cohort.
berichtet
Human trial
Increased skin pigmentation / darker naevi
Direct expression of the mechanism of action; for this reason regular dermatological skin monitoring is recommended.
erwarteter pharmakodynamischer Effekt
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Long-term safety
Long-term observational data over up to eight years and more than a thousand implants suggest a predominantly mild adverse-effect profile; a definitive benefit-risk assessment rests with the regulatory authorities.
Dermatological monitoring
Because of the pigmenting effect, the product information and literature recommend regular medical skin monitoring during treatment.
09
Regulatory voices
Direct statements from official assessment documents — paraphrased with date and source link.
FDAU.S. Food and Drug Administration
2019-10-08
FDA press release on the approval of Scenesse in 2019.
Scenesse is the first FDA-approved therapy to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria.
Approved by the FDA in 2019 as Scenesse (subcutaneous implant) to increase pain-free light exposure in adults with erythropoietic protoporphyria — prescription only.
2026-06-07
EU
Prescription
Approved by the EMA in 2014 (marketing authorization in early 2015) as Scenesse for the prevention of phototoxicity in adults with erythropoietic protoporphyria — prescription only.
2026-06-07
Germany
Prescription
Marketable and prescription-only in Germany via the central EMA approval; administered in specialized centers for porphyria patients.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.